Seeking Alpha

ImmunityBio: Anktiva's Launch Progresses - Bladder Cancer Drug May Be 'Real Deal'

ImmunityBio received FDA approval for ANKTIVA plus BCG for BCG-unresponsive bladder cancer in April. The drug has a unique mechanism of action. Immunity's early launch progress of Anktiva shows ...
Seeking Alpha

ImmunityBio: Still Too Early To Judge Anktiva, Although Clock Is Ticking

I maintain a Hold rating on ImmunityBio as Anktiva shows strong NMIBC data but the commercial uptake remains slow and uncertain. IBRX's Q2 revenues rose to $26.4M, but accumulated losses and lack of ...
Nasdaq

ImmunityBio Announces Positive Results Demonstrating ANKTIVA® as a Lymphocyte Stimulating Agent in Combination With Checkpoint Inhibitors in Non-Small Cell Lung Cancer

CULVER CITY, Calif.--(BUSINESS WIRE)-- ImmunityBio, Inc. (NASDAQ: IBRX), a clinical-stage immunotherapy company, today announced positive results from its ANKTIVA (nogapendekin alfa inbakicept) ...
Los Angeles Business Journal

New Sign-Off Propels ImmunityBio

Shares in ImmunityBio climbed in recent weeks in the wake of approval by Saudi Arabia for its drug Anktiva. Shares of Culver City-based immunotherapy company ImmunityBio Inc. had a huge runup in ...
Nasdaq

ImmunityBio Announces Permanent J-code (J9028) for ANKTIVA® Is Now Effective

CULVER CITY, Calif.--(BUSINESS WIRE)-- ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced the unique, permanent Healthcare Common Procedure Coding System (HCPCS) J-code ...